Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Hepatitis C reinfection after sustained virological response.
Midgard H, Bjøro B, Mæland A, Konopski Z, Kileng H, Damås JK, Paulsen J, Heggelund L, Sandvei PK, Ringstad JO, Karlsen LN, Stene-Johansen K, Pettersson JH, Dorenberg DH, Dalgard O. Midgard H, et al. Among authors: kileng h. J Hepatol. 2016 May;64(5):1020-1026. doi: 10.1016/j.jhep.2016.01.001. Epub 2016 Jan 11. J Hepatol. 2016. PMID: 26780289 Clinical Trial.
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Dore GJ, Altice F, Litwin AH, Dalgard O, Gane EJ, Shibolet O, Luetkemeyer A, Nahass R, Peng CY, Conway B, Grebely J, Howe AY, Gendrano IN, Chen E, Huang HC, Dutko FJ, Nickle DC, Nguyen BY, Wahl J, Barr E, Robertson MN, Platt HL; C-EDGE CO-STAR Study Group. Dore GJ, et al. Ann Intern Med. 2016 Nov 1;165(9):625-634. doi: 10.7326/M16-0816. Epub 2016 Aug 9. Ann Intern Med. 2016. PMID: 27537841 Clinical Trial.
Efficacy and safety of elbasvir/grazoprevir and sofosbuvir/pegylated interferon/ribavirin: A phase III randomized controlled trial.
Sperl J, Horvath G, Halota W, Ruiz-Tapiador JA, Streinu-Cercel A, Jancoriene L, Werling K, Kileng H, Koklu S, Gerstoft J, Urbanek P, Flisiak R, Leiva R, Kazenaite E, Prinzing R, Patel S, Qiu J, Asante-Appiah E, Wahl J, Nguyen BY, Barr E, Platt HL. Sperl J, et al. Among authors: kileng h. J Hepatol. 2016 Dec;65(6):1112-1119. doi: 10.1016/j.jhep.2016.07.050. Epub 2016 Aug 16. J Hepatol. 2016. PMID: 27542322 Clinical Trial.
Personalized treatment of hepatitis C genotype 1a in Norway and Sweden 2014-2016: a study of treatment outcome in patients with or without resistance-based DAA-therapy.
Kileng H, Kjellin M, Akaberi D, Bergfors A, Duberg AS, Wesslén L, Danielsson A, Gangsøy Kristiansen M, Gutteberg T, Goll R, Lannergård A, Lennerstrand J. Kileng H, et al. Scand J Gastroenterol. 2018 Oct-Nov;53(10-11):1347-1353. doi: 10.1080/00365521.2018.1511824. Epub 2018 Nov 5. Scand J Gastroenterol. 2018. PMID: 30394152
Effect of the baseline Y93H resistance-associated substitution in HCV genotype 3 for direct-acting antiviral treatment: real-life experience from a multicenter study in Sweden and Norway.
Kjellin M, Kileng H, Akaberi D, Palanisamy N, Duberg AS, Danielsson A, Kristiansen MG, Nöjd J, Aleman S, Gutteberg T, Goll R, Lannergård A, Lennerstrand J. Kjellin M, et al. Among authors: kileng h. Scand J Gastroenterol. 2019 Aug;54(8):1042-1050. doi: 10.1080/00365521.2019.1652846. Epub 2019 Aug 19. Scand J Gastroenterol. 2019. PMID: 31424972
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.
Howe AYM, Rodrigo C, Cunningham EB, Douglas MW, Dietz J, Grebely J, Popping S, Sfalcin JA, Parczewski M, Sarrazin C, de Salazar A, Fuentes A, Sayan M, Quer J, Kjellin M, Kileng H, Mor O, Lennerstrand J, Fourati S, Di Maio VC, Chulanov V, Pawlotsky JM, Harrigan PR, Ceccherini-Silberstein F, Garcia F; SHARED Collaborators. Howe AYM, et al. Among authors: kileng h. JHEP Rep. 2022 Feb 24;4(5):100462. doi: 10.1016/j.jhepr.2022.100462. eCollection 2022 May. JHEP Rep. 2022. PMID: 35434589 Free PMC article.
13 results